Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
2週酮酯治療在2型糖尿病及保留射出分數心衰竭患者中的隨機交叉試驗。
Circulation 2024-08-20
Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial.
急性心衰患者循環酮體水平的縱向變化:EMPA-Response-AHF試驗的事後分析。
J Card Fail 2023-03-14
The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1-3a CKD patients.
腎臟慢性疾病患者中肥胖G1-3a期階段的生酮飲食對減重的影響:隨機對照試驗。
Clin Kidney J 2023-12-05
Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.
Empagliflozin透過調節酮體代謝和氧化壓力,改善糖尿病心肌病的線粒體功能障礙。
Redox Biol 2024-02-02
The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator.
Empagliflozin誘導的代謝變化對2型糖尿病患者心臟功能的作用:一項隨機交叉磁共振成像研究,以胰島素作為比較劑。
Cardiovasc Diabetol 2024-03-13
Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial.
急性心肌梗塞後酮體水平及其與心臟標記物的相關性:EMMY 試驗的事後分析。
Cardiovasc Diabetol 2024-04-27
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety.
心衰竭與2型糖尿病中的Dapagliflozin:療效、心臟及腎臟效果、安全性。
World J Diabetes 2024-08-05